Oncolytics Bio Tacks On Cancer Combo Study with Merck KGaA, Pfizer

There’s a speed dating game of sorts happening as pharmaceutical companies that have approved cancer immunotherapies are testing their medications in combination with experimental drugs in hopes of reaching more patients. San Diego’s Oncolytics Biotech (NASDAQ: ONCY) has been an active participant in those combination efforts, with multiple pharmaceutical companies pairing its lead drug candidate, […]

Click to view original post